- Extramammary Paget Disease (EMPD) is a rare cutaneous malignancy primarily affecting apocrine gland-bearing areas, most commonly the vulva, scrotum, perianal region, and axilla.
- The market for EMPD treatment is evolving with improved diagnostic techniques and targeted therapies
- North America dominated the Extramammary Paget Disease market with the largest revenue share of 40.7% in 2024, driven by advanced healthcare infrastructure, early disease recognition, and the increasing adoption of immunotherapy and surgical innovations. The presence of leading research institutes, strong reimbursement policies, and a focus on rare cancer research contribute to the region's leadership
- Asia-Pacific is expected to be the fastest-growing region in the Extramammary Paget Disease market during the forecast period, with a projected CAGR of 24.1% from 2025 to 2032. Factors driving this growth include rising awareness of skin diseases, increasing healthcare spending, and improved access to dermatological and oncological services in countries such as Japan, China, and South Korea
- The primary segment dominated the Extramammary Paget Disease with the largest revenue share of 68.3% in 2024, primarily due to its higher incidence rate in aging populations and greater clinical detection
